JP2019528694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528694A5 JP2019528694A5 JP2019510931A JP2019510931A JP2019528694A5 JP 2019528694 A5 JP2019528694 A5 JP 2019528694A5 JP 2019510931 A JP2019510931 A JP 2019510931A JP 2019510931 A JP2019510931 A JP 2019510931A JP 2019528694 A5 JP2019528694 A5 JP 2019528694A5
- Authority
- JP
- Japan
- Prior art keywords
- bispecific antibody
- scfv
- seq
- domain
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378388P | 2016-08-23 | 2016-08-23 | |
| US62/378,388 | 2016-08-23 | ||
| PCT/EP2017/071104 WO2018037000A1 (en) | 2016-08-23 | 2017-08-22 | Anti-vegf-a and anti-ang2 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528694A JP2019528694A (ja) | 2019-10-17 |
| JP2019528694A5 true JP2019528694A5 (enExample) | 2020-10-01 |
| JP7174691B2 JP7174691B2 (ja) | 2022-11-17 |
Family
ID=59714013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510931A Active JP7174691B2 (ja) | 2016-08-23 | 2017-08-22 | 抗ｖｅｇｆ－ａおよび抗ａｎｇ２抗体ならびにそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10836819B2 (enExample) |
| EP (1) | EP3504237A1 (enExample) |
| JP (1) | JP7174691B2 (enExample) |
| KR (1) | KR102543878B1 (enExample) |
| CN (1) | CN109863171B (enExample) |
| AU (1) | AU2017315075B2 (enExample) |
| IL (1) | IL264962B2 (enExample) |
| MA (1) | MA46036A (enExample) |
| WO (1) | WO2018037000A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
| WO2021259200A1 (zh) * | 2020-06-22 | 2021-12-30 | 信达生物制药(苏州)有限公司 | 抗ang-2抗体及其用途 |
| PE20230986A1 (es) | 2020-09-04 | 2023-06-21 | Hoffmann La Roche | Anticuerpo que se une a vegf-a y ang2, y metodos de uso |
| WO2022212360A1 (en) * | 2021-03-30 | 2022-10-06 | Abpro Corporation | Methods for treating choroidal neovascularization using anti-ang2 x vegf multi-specific antibodies |
| CN116265487B (zh) * | 2021-12-16 | 2025-01-10 | 三优生物医药(上海)有限公司 | 抗ang2-vegf双特异性抗体及其用途 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN119403517A (zh) | 2022-04-29 | 2025-02-07 | Inqb8医疗科技有限责任公司 | 用于可控地和选择性地阻塞、限制和转向患者的脉管系统内的流的系统、设备和方法 |
| US11883030B2 (en) | 2022-04-29 | 2024-01-30 | inQB8 Medical Technologies, LLC | Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature |
| WO2024085606A1 (ko) * | 2022-10-20 | 2024-04-25 | (주)니오테스바이오 | 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용 |
| CN116462768B (zh) * | 2023-06-13 | 2023-09-22 | 浙江时迈药业有限公司 | 针对folr1的双特异性抗体及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US5650490A (en) | 1994-10-07 | 1997-07-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 2 |
| HUP0302779A3 (en) | 2000-06-23 | 2005-12-28 | Schering Ag | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| ES2371083T3 (es) * | 2004-12-21 | 2011-12-27 | Medimmune Limited | Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos. |
| EP2518083A3 (en) * | 2005-12-15 | 2012-12-05 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer |
| ES2395842T3 (es) | 2006-01-17 | 2013-02-15 | Synthon Biopharmaceuticals B.V. | Composiciones y métodos para la humanización y optimización de N-glicanos en plantas |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| US8216571B2 (en) | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
| US8507656B2 (en) | 2008-01-28 | 2013-08-13 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| CN102250248A (zh) * | 2011-06-15 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗vegf/ang2双特异性抗体及其应用 |
| ES2749349T3 (es) * | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| LT3495387T (lt) * | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| KR20150063847A (ko) * | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-A/항 Ang2 이중 특이 항체 |
| KR20170003651A (ko) * | 2014-05-07 | 2017-01-09 | 메디뮨 엘엘씨 | 항-ａｎｇ2 항체의 사용 방법 |
| CA2963175A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| AR103477A1 (es) | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
-
2017
- 2017-08-22 EP EP17758124.6A patent/EP3504237A1/en active Pending
- 2017-08-22 AU AU2017315075A patent/AU2017315075B2/en active Active
- 2017-08-22 US US16/327,207 patent/US10836819B2/en active Active
- 2017-08-22 WO PCT/EP2017/071104 patent/WO2018037000A1/en not_active Ceased
- 2017-08-22 KR KR1020197007756A patent/KR102543878B1/ko active Active
- 2017-08-22 JP JP2019510931A patent/JP7174691B2/ja active Active
- 2017-08-22 MA MA046036A patent/MA46036A/fr unknown
- 2017-08-22 CN CN201780064426.5A patent/CN109863171B/zh active Active
- 2017-08-22 IL IL264962A patent/IL264962B2/en unknown
-
2020
- 2020-10-14 US US17/070,157 patent/US11566068B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535828A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| EP4286415A3 (en) | Humanized antigen-binding domains against cd19 and methods of use | |
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| JP2009539348A5 (enExample) | ||
| WO2010095031A3 (en) | Humanized antibodies that bind to cd19 and their uses | |
| IL299221A (en) | Cd3 binding antibodies | |
| JP2020514277A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2020504101A5 (enExample) | ||
| WO2011051327A3 (en) | Small antibody-like single chain proteins | |
| JP2017114866A5 (enExample) | ||
| JP2022523442A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| NZ601342A (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
| JP2015504421A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2021501744A5 (enExample) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
| JP2016514463A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav |